ArticleStem cell research & therapy2025
Ultrasound assisted homing of human umbilical cord mesenchymal stem cells promotes recovery from acute respiratory distress syndrome.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Recent trends in modified mesenchymal stromal cells: engineering approaches and international regulatory landscape.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundHuman umbilical cord mesenchymal stem cells (hUC-MSCs) show potential for treating acute respiratory distress syndrome (ARDS), however, their homing to the lungs and survival time are insufficient. In this study, we evaluated whether pulsed focus ultrasound (pFUS) could promote the homing and prolonged retention of hUC-MSCs in the lungs of ARDS mice and explored the mechanisms involved.
methodsMice were divided into four groups: the NC group, the LPS group, the MSCs group, and the pFUS + MSCs group. Except for the NC group, the other three groups were constructed as ARDS models and given PBS, MSCs and pFUS + MSCs interventions. hUC-MSCs were used to assess lung tissue injury by HE staining, inflammatory cell count in alveolar lavage fluid (BALF), and expression of Tnf, Il1b and Il6 in the lung tissues; and apoptosis and proliferation in the lung tissues were assessed by TUNEL and immunofluorescence. Bioluminescence imaging was used to detect the homing rate and survival of hUC-MSCs in mouse lungs from 1 to 7 days. Cxcl5 and Igf1 was found to be differentially expressed and highly enriched by mRNA sequencing in MSC and sonicated groups and verified by PCR combined with ELISA.
resultsCompared with the LPS group, the lung inflammatory infiltrate and lung tissue damage in the MSCs group and pFUS + MSC group were alleviated, the number of inflammatory cells in the BALF and the expression of Tnf, Il1b and Il6 in the lung tissues were reduced, the expression of TUNEL-positive cells was reduced, and the expression of PCNA-positive cells was increased, and the decrease or increase was more significant in the pFUS + MSC group (P < 0.05). pFUS increased the number of hUC-MSCs homing in the lungs and prolonged lung survival to day 6 and significantly up-regulated lung tissue levels of SDF-1, ICAM-1, CXCL5 and IGF-1 compared to the MSCs group (P < 0.05).
conclusionspFUS preconditioning may improve lung homing and prolong survival of hUC-MSCs by upregulating the levels of homing-associated factors SDF-1, ICAM-1, CXCL5 and IGF-1, which in turn improves ARDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.